Business
BioMark Diagnostics Collaborative Lung Cancer Screening Project Honored by ADRIQ during the 35th Innovation Awards Gala
Recognition of BioMark Leadership in Early Cancer Detection Validates Commercialization Trajectory of Multimodal Lung Cancer Screening PlatformVancouver, British Columbia--(Newsfile Corp. - December 1, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for early cancer detection, is honored to announce that the Company and its research partners from the Institut universitaire de cardiologie et de pneumologie de...
About this update from Biomark Diagnostics, Inc.
[{"type":"text","content":"Recognition of BioMark Leadership in Early Cancer Detection Validates Commercialization Trajectory of Multimodal Lung Cancer Screening Platform","length":143,"tagName":"p","attribs":{"class":"nfSubHeading"},"className":""},{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - December 1, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for early cancer detection, is honored to announce that the Company and its research partners from the Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval (IUCPQ-UL) were awarded the Innovation Award from Industrial Research Cluster during the 35th annual ADRIQ Innovation Awards Gala. The award ceremony, held on November 27, 2025, celebrated the collaboration between Quebec-based BioMark Diagnostic Solutions, Astra Zeneca Canada, Pfizer Canada and the IUCPQ-UL research team (Dr. Philippe Joubert and Dr. Yohan Bossé).","length":757,"tagName":"p"},{"type":"text","content":"The recognition highlights the successful development of an innovative multimodal approach designed to predict lung cancer risk, enabling simpler, earlier, and less invasive screening. At the heart of this initiative is BioMark's metabolomic blood test, which combines the analysis of blood biomarkers with clinical data using artificial intelligence to calculate the probability of lung cancer presence. The award highlights the power of combining academic excellence with industrial innovation to bring life-saving diagnostic tools to market.","length":548,"tagName":"p"},{"type":"text","content":"Revolutionizing Lung Cancer Screening in Quebec and Beyond","length":58,"tagName":"p"},{"type":"text","content":"This groundbreaking project, valued at $4.42 million, was made possible through funding from the Government of Quebec via the Quebec Consortium for Drug Discovery (CQDM), with support from strategic partners including AstraZeneca Canada, Pfizer Canada, and the IUCPQ Foundation. This major project serves as a significant validation of BioMark's core technology and its commercialization strategy. The project was also instrumental in the creation of a unique biobank derived from Quebec's government lung cancer screening program, which consolidates clinical data and biological sam...